Hologic (HOLX) Set to Announce Quarterly Earnings on Thursday

Hologic (NASDAQ:HOLX) will issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.98 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. During the same period in the previous year, the company posted $1.07 EPS. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Hologic Trading Down 1.1 %

Shares of NASDAQ:HOLX opened at $75.77 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The business’s 50-day moving average is $76.08 and its 200 day moving average is $72.88. The firm has a market capitalization of $17.79 billion, a P/E ratio of 35.91, a P/E/G ratio of 2.57 and a beta of 1.00. Hologic has a 1 year low of $64.02 and a 1 year high of $87.88.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. UBS Group increased their price objective on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Wednesday, April 10th. Raymond James raised their price target on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Finally, Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $87.00.

Insider Buying and Selling

In other news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.